(5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)(CAS: 38562-01-5)

The compound (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CAS: 38562-01-5) is subject to various regulations including GHS classification, REACH regulations, FDA guidelines for pharmaceutical use, and EPA regulations for environmental handling. It is important to follow the specific guidelines related to its classification and handling.

Yes, there are alternatives to (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CAS: 38562-01-5) in synthesis. Common alternatives include other prostaglandin derivatives and prodrugs of prostaglandins. These alternatives can be used depending on the specific requirements of the synthesis process.

The market and research trends for (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CAS: 38562-01-5) are focused on its potential therapeutic applications, particularly in the treatment of inflammatory and pain conditions. Research is also exploring its role in drug delivery systems and its interactions with other biological molecules.

Waste containing (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CAS: 38562-01-5) should be handled according to local and national regulations. Typically, it should be collected in appropriate containers, labeled, and disposed of through professional waste disposal services. Environmental precautions include ensuring no contamination of water sources during disposal.